| Field | Specification |
|---|---|
| Target | |
| Alternative names | Bcl-2-like protein 2;Bcl2-L-2;Apoptosis regulator Bcl-W;BCL2L2;BCLW, KIAA0271; |
| Gene ID | |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence in the middle region of human BCL2L2, identical to the related rat and mouse sequences. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets bcl-2-like protein 2 (gene BCL2L2) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF and flow cytometry. The predicted molecular weight is 20.7 kDa, and the supplier reports an observed band at about 21 kDa.
Bcl-w (BCL2L2) is an anti-apoptotic member of the Bcl-2 family that binds pro-apoptotic partners such as BAX to promote cell survival. It is required for the survival of Sertoli and germ cells during spermatogenesis and supports neuronal survival.
| Target | Bcl-2-like protein 2 (gene BCL2L2; UniProt Q92843, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg thimerosal; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 20.7 kDa |
| Observed MW | 21 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| IHC (paraffin sections) | 0.5–1 µg/mL (Human, Rat, Mouse) |
|---|---|
| Western blot | 0.1–0.5 µg/mL (Human, Rat, Mouse) |
| IHC (frozen sections) | 0.5–1 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 0.5–1 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human A549 cells, human K562 cells, human U-937 cells, human HeLa cells, human A431 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human rectal cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with a confirmed signal (flow cytometry): PC-3 cells.
Immunogen
Synthetic peptide from the middle region of human BCL2L2. The peptide sequence is conserved in rat and mouse.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places bcl-2-like protein 2 in the mitochondrion membrane. Tissue expression noted by UniProt (human): Expressed (at protein level) in a wide range of tissues with highest levels in brain, spinal cord, testis, pancreas, heart, spleen and mammary glands. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
